Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077.


Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and more efficacious immunotherapeutic strategies for the treatment of lymphoma and leukemia. With blinatumomab (MT103) a first antibody, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis, is now available for clinical evaluation. Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T cell engager. Here, we review the current progress in development of blinatumomab for treatment of patients with CD19-expressing hematological malignancies.

Publication types

  • Review

MeSH terms

  • Antibodies, Bispecific / therapeutic use*
  • Antigens, CD19 / immunology
  • B-Lymphocytes / cytology
  • B-Lymphocytes / immunology
  • Cytotoxicity, Immunologic / drug effects
  • Cytotoxicity, Immunologic / immunology
  • Humans
  • Immunotherapy / methods*
  • Leukemia / immunology
  • Leukemia / therapy*
  • Lymphoma / immunology
  • Lymphoma / therapy*
  • Models, Immunological
  • T-Lymphocytes / cytology
  • T-Lymphocytes / immunology*


  • Antibodies, Bispecific
  • Antigens, CD19
  • blinatumomab